AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27215279 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg recombinant HepB vaccine (adults ages 15-24)
Number of subjects: 0
Study 27215279 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dosage of HepB vaccine (adults ages 25 and older)
Number of subjects: 0
Study 23281382 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of lamivudine (LAM) 100 mg/d plus adefovir dipivoxyl (ADV) 10 mg/d
Number of subjects: 81
Study 23281382 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxyl (ADV) 10 mg/d
Number of subjects: 81
Study 23281382 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of lamivudine (LAM) and adefovir dipivoxyl (ADV)
Number of subjects: 81
Study 20179232 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen sulfate (Hyd-Sulfate) capsule of AZD6244 (75 mg twice daily)
Number of subjects: 59
Study 20179232 — intervention group
Group type: COMPARATOR
Intervention: Hydrogen sulfate (Hyd-Sulfate) capsule
Number of subjects: 59
Study 17268205 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular therapy (biventricular therapy + defibrillator)
Number of subjects: 18
Study 17268205 — intervention group
Group type: COMPARATOR
Intervention: Control group (implantable cardioverter-defibrillator alone)
Number of subjects: 18
Study 17268205 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular therapy
Number of subjects: 18
Study 17268205 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 15592021 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic radical nephrectomy
Number of subjects: 102
Study 15592021 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal laparoscopic radical nephrectomy
Number of subjects: 102
Study 12113615 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of rocuronium 0.06 mg kg(‐1) followed 2 min later by rocuronium 0.54 mg kg(‐1)
Number of subjects: 75
Study 12113615 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of 0.10 mg kg(‐1) followed 2 min later by rocuronium 0.50 mg kg(‐1)
Number of subjects: 75
Study 12113615 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of rocuronium 0.06 mg kg(‐1) followed 3 min later by administration 0.54 mg kg(‐1)
Number of subjects: 75
Study 12113615 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of 0.10 mg kg(‐1) followed 3 min later by injection of 0.50 mg kg(‐1)
Number of subjects: 75
Study 12113615 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection followed 3 min later by rocuronium 0.60 mg kg(‐1)
Number of subjects: 75
Study 9585800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir plus saquinavir (200 mg saquinavir and 300 mg ritonavir)
Number of subjects: 6
Study 9585800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir plus saquinavir (200 mg saquinavir and 600 mg ritonavir)
Number of subjects: 6
Study 9585800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir plus saquinavir (400 mg saquinavir and 300 mg ritonavir)
Number of subjects: 6
Study 9585800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir plus saquinavir (400 mg saquinavir and 600 mg ritonavir)
Number of subjects: 6
Study 9585800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir plus saquinavir (600 mg saquinavir and 200 mg ritonavir)
Number of subjects: 6
Study 9585800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir plus saquinavir (600 mg saquinavir and 600 mg ritonavir)
Number of subjects: 6
Study 9585800 — intervention group
Group type: COMPARATOR
Intervention: Saquinavir alone
Number of subjects: 6
Study 8590489 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple airway manoeuvre (TAM)
Number of subjects: 100
Study 8590489 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard method)
Number of subjects: 100
Study 2146885 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin 50 micrograms
Number of subjects: 8
Study 2146885 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin 100 micrograms
Number of subjects: 8
Study 2146885 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (all doses)
Number of subjects: 8
Study 2146885 — intervention group
Group type: COMPARATOR
Intervention: Urodilatin 25 micrograms
Number of subjects: 8
Study 2146885 — intervention group
Group type: COMPARATOR
Intervention: ANF-(99-126) 50 micrograms
Number of subjects: 8
Study 2146885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 404621 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin infusion (0.1 units/kg/hour)
Number of subjects: 14
Study 404621 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin injection
Number of subjects: 14
Study 31847976 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 60
Study 31847976 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy
Number of subjects: 60
Study 31847976 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 29490371 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 541
Study 29490371 — intervention group
Group type: COMPARATOR
Intervention: Transitional Work
Number of subjects: 541
Study 26816011 — intervention group
Group type: EXPERIMENTAL
Intervention: More-intensive belatacept regimen
Number of subjects: 666
Study 26816011 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-intensive belatacept regimen
Number of subjects: 666
Study 26816011 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine regimen
Number of subjects: 666
Study 24492859 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment (IST) for malaria using artemether-lumefantrine (AL) with a six dose regimen.
Number of subjects: 5233
Study 24492859 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment (IST) for malaria.
Number of subjects: 5233
Study 24492859 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IST intervention).
Number of subjects: 5233
Study 23027646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting Edge Tests to assess diabetes complications
Number of subjects: 1334
Study 23027646 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual Evaluations
Number of subjects: 1334
Study 23027646 — intervention group
Group type: EXPERIMENTAL
Intervention: Help Others
Number of subjects: 1334
Study 23027646 — intervention group
Group type: EXPERIMENTAL
Intervention: Better Care for Diabetes
Number of subjects: 1334
Study 20870985 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular brachial plexus block (ICB)
Number of subjects: 1020
Study 17589421 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine + morphine (MM)
Number of subjects: 100
Study 17589421 — intervention group
Group type: COMPARATOR
Intervention: morphine + remifentanil (MR)
Number of subjects: 100
Study 17286117 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniform-grey backgrounds
Number of subjects: 0
Study 17286117 — intervention group
Group type: COMPARATOR
Intervention: Natural-scene backgrounds
Number of subjects: 0
Study 17286117 — intervention group
Group type: COMPARATOR
Intervention: Fractal noise backgrounds
Number of subjects: 0
Study 12419714 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.9%
Number of subjects: 48
Study 12419714 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 1.2%
Number of subjects: 48
Study 12419714 — intervention group
Group type: COMPARATOR
Intervention: Propofol 100‐150 microgram.kg(‐1).min(‐1)
Number of subjects: 48
Study 10025899 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with alkylating agents
Number of subjects: 25
Study 10025899 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea and other non-alkylating agents
Number of subjects: 25
Study 10025899 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 25
Study 7740509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Ardeparin) administered subcutaneously
Number of subjects: 0
Study 7740509 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) administered subcutaneously
Number of subjects: 0
Study 7740509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Ardeparin) administered intravenously
Number of subjects: 0
Study 7740509 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) administered intravenously
Number of subjects: 0
Study 7740509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Ardeparin)
Number of subjects: 0
Study 7740509 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study 1696921 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomoparan (Org 10172)
Number of subjects: 6
Study 1696921 — intervention group
Group type: COMPARATOR
Intervention: Acenocoumarol
Number of subjects: 6
Study 7042603 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 450 mg daily (Regimen A)
Number of subjects: 35
Study 7042603 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 1200 mg once a month (Regimen B)
Number of subjects: 35
Study 31597662 — intervention group
Group type: EXPERIMENTAL
Intervention: ME-344 10 mg/kg intravenous on days 8, 15, and 21
Number of subjects: 42
Study 31597662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31597662 — intervention group
Group type: EXPERIMENTAL
Intervention: ME-344 (in subgroup with vascular normalization)
Number of subjects: 42
Study 31597662 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in subgroup with vascular normalization)
Number of subjects: 42
Study 31758639 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus (SLE)
Number of subjects: 5047
Study 31758639 — intervention group
Group type: COMPARATOR
Intervention: Non-SLE individuals (control)
Number of subjects: 5047
Study 28887117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) treatment (14∼16 J/cm2)
Number of subjects: 0
Study 28887117 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (0 J/cm2)
Number of subjects: 0
Study 28887117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) treatment
Number of subjects: 0
Study 25790936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 25
Study 25790936 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive plate osteosynthesis (MIPO)
Number of subjects: 25
Study 23710347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 139
Study 21159325 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed in-session resistance
Number of subjects: 0
Study 21159325 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported motivation measures (Change Questionnaire & Client Motivational for Therapy Scale)
Number of subjects: 0
Study 21159325 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing prior to CBT
Number of subjects: 0
Study 19076544 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupine
Number of subjects: 39
Study 19076544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea
Number of subjects: 39
Study 19076544 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy
Number of subjects: 39
Study 17317428 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric home hospitalization service (GHHS)
Number of subjects: 73
Study 17317428 — intervention group
Group type: COMPARATOR
Intervention: General medical ward (GMW)
Number of subjects: 73
Study 15521851 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 2 mg b.d.
Number of subjects: 2612
Study 15521851 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.d.
Number of subjects: 2612
Study 15521851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2612
Study 15521851 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod (both dosages)
Number of subjects: 2612
Study 10561948 — intervention group
Group type: COMPARATOR
Intervention: Prenolol 50 mg
Number of subjects: 12
Study 10561948 — intervention group
Group type: COMPARATOR
Intervention: Prenolol 100 mg
Number of subjects: 12
Study 8919037 — intervention group
Group type: EXPERIMENTAL
Intervention: Annexin I mRNA expression in keratinizing squamous cells in keratotic type seborrhoeic keratosis
Number of subjects: 0
Study 8919037 — intervention group
Group type: EXPERIMENTAL
Intervention: Annexin I mRNA expression in keratinocytes at the periphery of the horn pearl in well-differentiated squamous cell carcinoma
Number of subjects: 0
Study 8919037 — intervention group
Group type: EXPERIMENTAL
Intervention: Annexin I mRNA expression at the border between involved and noninvolved skin in psoriasis vulgaris
Number of subjects: 0
Study 8919037 — intervention group
Group type: EXPERIMENTAL
Intervention: Annexin I mRNA expression in dyskeratotic epidermal keratinocytes in keratosis follicularis Darier
Number of subjects: 0
Study 8919037 — intervention group
Group type: COMPARATOR
Intervention: Annexin I mRNA expression in basal and suprabasal cells of normal epidermis
Number of subjects: 0
Study 8919037 — intervention group
Group type: COMPARATOR
Intervention: Annexin I mRNA expression in tumour cells in basal cell carcinoma
Number of subjects: 0
Study 1747577 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg twice daily
Number of subjects: 49
Study 1747577 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily
Number of subjects: 49
Study 1747577 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg plus slow release nifedipine 20 mg twice daily
Number of subjects: 49
Study 1747577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 6621623 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of 3500 IU of heparin subcutaneously every eight hours (Group 1)
Number of subjects: 79
Study 6621623 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted dose of heparin to maintain activated partial thromboplastin time between 31.5 and 36 seconds (Group 2)
Number of subjects: 79
Study 31443692 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) at 200 mmHg, twice daily for 6 months
Number of subjects: 37
Study 31443692 — intervention group
Group type: COMPARATOR
Intervention: Control group at 60 mmHg, twice daily for 6 months
Number of subjects: 37
Study 31443692 — intervention group
Group type: EXPERIMENTAL
Intervention: RIC group
Number of subjects: 37
Study 28592257 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxacalcitol ointment applied twice a day for 8 weeks
Number of subjects: 8
Study 28592257 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxacalcitol ointment
Number of subjects: 8
Study 25683077 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml of 25% dextrose orally just before laser therapy
Number of subjects: 24
Study 25683077 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia with paracaine eye drops
Number of subjects: 24
Study 22230181 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional development program for early childhood educators led by a speech-language pathologist, including 18 hours of group training and 3 individual coaching sessions.
Number of subjects: 20
Study 22230181 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional development program for early childhood educators led by a speech-language pathologist.
Number of subjects: 20
Study 20413380 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciaglia Blue Rhino technique (n=35)
Number of subjects: 70
Study 20413380 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciaglia Blue Dolphin technique (n=35)
Number of subjects: 70
Study 18639659 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue spray and collagen patch applied to the axillary fossa
Number of subjects: 50
Study 18639659 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 50
Study 15673354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention social workers received baseline education in advance care planning, structured discussions, formal reviews, flagging of advance directives, and feedback on care congruence.
Number of subjects: 139
Study 15673354 — intervention group
Group type: COMPARATOR
Intervention: Control social workers received an educational training session on New York State law regarding advance directives but no additional training or interventions.
Number of subjects: 139
Study 11791023 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-treated hypertension
Number of subjects: 6000
Study 11791023 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-treated hypertension with target blood pressure below 130/85
Number of subjects: 6000
Study 11791023 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequately treated hypertensives
Number of subjects: 6000
Study 11791023 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated subjects with blood pressure 140/90 or above
Number of subjects: 6000
Study 10347347 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 401
Study 10347347 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 401
Study 8610239 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m2 on day 1 (Group A)
Number of subjects: 86
Study 8610239 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m2 on days 1 and 8 (Group B)
Number of subjects: 86
Study 8610239 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m2 on days 1 and 15 and 12.5 mg/m2 on day 8 (Group C)
Number of subjects: 86
Study 1934538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 10 mg twice daily
Number of subjects: 0
Study 1934538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg twice daily
Number of subjects: 0
Study 1934538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 5 mg twice daily
Number of subjects: 0
Study 6304907 — intervention group
Group type: EXPERIMENTAL
Intervention: Veralipride (100 mg per day for 20 days)
Number of subjects: 43
Study 6304907 — intervention group
Group type: COMPARATOR
Intervention: Natural estrogens (1.25 mg for 20 days)
Number of subjects: 43
Study 30760299 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help (GSH) treatment comprising eight sessions followed by three booster sessions
Number of subjects: 60
Study 30760299 — intervention group
Group type: COMPARATOR
Intervention: Placebo-inspired waitlist control group receiving weekly messages with positive expectations
Number of subjects: 60
Study 30760299 — intervention group
Group type: COMPARATOR
Intervention: Pure waitlist control group receiving weekly messages asking to fill in a questionnaire
Number of subjects: 60
Study 29609573 — intervention group
Group type: EXPERIMENTAL
Intervention: Public awareness of H7N9
Number of subjects: 2969
Study 29609573 — intervention group
Group type: EXPERIMENTAL
Intervention: Public awareness of MERS
Number of subjects: 2969
Study 29609573 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge score for H7N9
Number of subjects: 2969
Study 29609573 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge score for MERS
Number of subjects: 2969
Study 29609573 — intervention group
Group type: EXPERIMENTAL
Intervention: Sources of outbreak information
Number of subjects: 2969
Study 27487357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led, home-based medication management intervention delivered within 7 days after hospital discharge
Number of subjects: 155
Study 27487357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led, home-based medication management intervention
Number of subjects: 155
Study 24836205 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren (10 mg/kg in morning, 10 mg/kg midday, and 20 mg/kg in evening)
Number of subjects: 238
Study 24836205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 24836205 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren (in subgroup not using chronic inhaled tobramycin)
Number of subjects: 238
Study 24836205 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in subgroup not using chronic inhaled tobramycin)
Number of subjects: 238
Study 24836205 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren
Number of subjects: 238
Study 22854665 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR9 agonist (CPG 7909) with pneumococcal conjugate vaccine (Prevnar, Pfizer)
Number of subjects: 40
Study 22854665 — intervention group
Group type: COMPARATOR
Intervention: Placebo with pneumococcal conjugate vaccine (Prevnar, Pfizer)
Number of subjects: 40
Study 20795842 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol therapy (100 mg/day for 5 weeks)
Number of subjects: 15
Study 20795842 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol therapy
Number of subjects: 15
Study 17040921 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA(A) receptor immunohistochemistry analysis in Huntington's disease cases
Number of subjects: 35
Study 17040921 — intervention group
Group type: COMPARATOR
Intervention: GABA(A) receptor immunohistochemistry analysis in control cases
Number of subjects: 35
Study 17560868 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 1 mg plus drospirenone 2 mg
Number of subjects: 56
Study 17560868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 15090932 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 3-202 (50 mg)
Number of subjects: 18
Study 15090932 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 3-202 (100 mg)
Number of subjects: 18
Study 15090932 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 3-202 (200 mg)
Number of subjects: 18
Study 15090932 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 3-202 (400 mg)
Number of subjects: 18
Study 15090932 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 3-202 (all doses)
Number of subjects: 18
Study 15090932 — intervention group
Group type: COMPARATOR
Intervention: Sinemet 25/100 (control)
Number of subjects: 18
Study 10929336 — intervention group
Group type: EXPERIMENTAL
Intervention: Halm-Zielke Instrumentation (HZI)
Number of subjects: 29
Study 9237780 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 40
Study 9237780 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylureas
Number of subjects: 40